NASDAQ:UTHR

United Therapeutics Stock Forecast

etoro logo Buy UTHR
*Your capital is at risk
$471.92
+5.52 (+1.18%)
At Close: Nov 17, 2025
AI Analysis AI Analysis of UTHR
AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment
Trading Strategy
PDF

Evaluation of United Therapeutics Corporation stock downgraded after the last trading session
(Updated on Nov 17, 2025)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Buy or Hold candidate since Oct 29, 2025 Gain 3.65%

The United Therapeutics Corporation stock price gained 1.18% on the last trading day (Monday, 17th Nov 2025), rising from $466.40 to $471.92. It has now gained 6 days in a row. It is not often that stock manage to gain so many days in a row, and falls for a day or two should be expected. During the last trading day the stock fluctuated 2.76% from a day low at $463.95 to a day high of $476.76. The price has risen in 8 of the last 10 days and is up by 7.58% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 79 thousand more shares were traded than the day before. In total, 481 thousand shares were bought and sold for approximately $227.08 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 35.53% during the next 3 months and, with a 90% probability hold a price between $603.20 and $702.61 at the end of this 3-month period.

UTHR Signals & Forecast

The United Therapeutics Corporation stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $460.60 and $442.40. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Tuesday, October 28, 2025, and so far it has risen 13.62%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for United Therapeutics Corporation stock

United Therapeutics Corporation finds support from accumulated volume at $455.32 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $12.81 between high and low, or 2.76%. For the last week, the stock has had daily average volatility of 2.73%.

Since the United Therapeutics Corporation has been rising for 6 days in a row, the risk over the next couple of days has increased. As we cannot be certain with regards to the size of the reaction, we urge caution.

Our recommended stop-loss: $453.96 (-3.81%) (This stock has medium daily movements and this gives medium risk. The RSI14 is 78 and this increases the risk substantially. There is a buy signal from a pivot bottom found 14 days ago.)

Trading Expectations (UTHR) For The Upcoming Trading Day Of Tuesday 18th

For the upcoming trading day on Tuesday, 18th we expect United Therapeutics Corporation to open at $470.88, and during the day (based on 14 day Average True Range), to move between $465.28 and $478.56, which gives a possible trading interval of +/-$13.29 (+/-2.86%) up or down from last closing price. If United Therapeutics Corporation takes out the full calculated possible swing range there will be an estimated 2.86% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $455.32, some $16.60 (3.52%) from the current price of $471.92, our system finds the risk reward attractive.

Is United Therapeutics Corporation stock A Buy?

United Therapeutics Corporation holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Hold candidate.

Current score: 0.000 Hold/Accumulate Downgraded

Zero in score indicates that our system is expecting high volatility and risk for the following trading day. Given the latest developments, we cannot determine the next direction as it may go both ways.

Predicted Fair Opening Price

Predicted fair opening price on November 18, 2025 - $470.88 ( 0.221%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk

UTHR Performance

Trading levels for UTHR

Full Access. No Commitment. 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 5 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 483.69 2.49%
R2 478.79 1.46%
R1 475.77 0.82%
Price 471.92
S1 465.98 -1.26%
S2 462.96 -1.90%
S3 458.07 -2.94%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 0 -
R1 0 -
Price 471.92
S1 455.32 -3.52%
S2 417.57 -11.52%
S3 404.81 -14.22%

FAQ

What is the symbol for United Therapeutics Corporation Stock and on which exchange is it traded?
The symbol for United Therapeutics Corporation is UTHR and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell United Therapeutics Corporation Stock?
United Therapeutics Corporation holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Hold candidate.

How to buy United Therapeutics Corporation Stock?
United Therapeutics Corporation Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy United Therapeutics Corporation Stock.

What's the current price of United Therapeutics Corporation Stock?
As of the end of day on the Nov 17, 2025, the price of an United Therapeutics Corporation (UTHR) share was $471.92.

What is the 52-week high and low for United Therapeutics Corporation Stock?
The 52-week high for United Therapeutics Corporation Stock is $479.50 and the 52-week low is $266.98.

What is the market capitalization of United Therapeutics Corporation Stock?
As of the Nov 17, 2025, the market capitalization of United Therapeutics Corporation is 21.083B.

When is the next earnings date for United Therapeutics Corporation?
The upcoming earnings date for United Therapeutics Corporation is Feb 25, 2026.
Click to get the best stock tips daily for free!
ABOUT UNITED THERAPEUTICS CORPORATION
United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE